Clinical trial NCT01435018: Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS
Official title: A Randomized Comparison of Three Regimens of Chemotherapy With Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: HIV-1 Infection
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Sponsor class: NETWORK
Collaborators: name: National Institute of Allergy and Infectious Diseases (NIAID)
name: National Cancer Institute (NCI)
name: National Institute of Dental and Craniofacial Research (NIDCR)
name: AIDS Malignancy Consortium
First posted: 2011-09-15
Enrollment: 334
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was done to compare the safety and efficacy of three combination treatments for Kaposi's Sarcoma (KS) and AIDS:

1. Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) (ET+ART),
2. Bleomycin and Vincristine (BV) plus co-formulated EFV/FTC/TDF (BV+ART),
3. Paclitaxel (PTX) plus co-formulated EFV/FTC/TDF (PTX+ART).

Detailed description: The study consisted of four steps. Study duration was up to 240 weeks.

At the study Step 1 entry, participants were randomized with equal probability to each of the three regimens (ET+ART, BV+ART, PTX+ART). The original target sample size was 706. Randomization was stratified by:

1. Screening CD4 lymphocyte cell count (\<100, \>=100 cells/mm³), and
2. Country.

For participants who had an initial Independent Endpoint Review Committee (IERC) confirmed KS response and subsequent IERC-confirmed KS progression, and who, in the opinion of the investigator and with concurrence of the protocol Clinical Management Committee (CMC), could potentially have benefitted from another course of the same chemotherapy utilized in Step 1, entered Step 2. (Please see details on Step 2 eligibility.)

In Step 3, participants were randomized with equal probability to one of the two chemotherapy arms not utilized in Step 1. (Please see details on Step 3 eligibility.)

In Step 4, participants were assigned to the remaining study-provided chemotherapy not given in Step 1, Step 2 or Step 3. (Please see details on Step 4 eligibility.)

Step 1 visits occurred at screening, entry and weeks 3, 6, 9, 12, 15, 18, 21,24, 27, 30, 33, 36, 39, 42, 45, 48, 60, 72, 84 and 96 from study entry. Visits for Steps 2, 3 and 4 were scheduled at entry and weeks 3, 6, 9, 12, 15, 18, 21,24, 27, 30, 33, 36, 39, 42, 45, 48, 60, 72, 84 and 96 from the corresponding step entry date. Key evaluations included targeted physical examination, clinical assessment, KS examination, hematology, chemistry, pregnancy testing (for women of reproductive potential), and pulse oximetry for participants on BV+ART. CD4 count and HIV viral load were obtained every 12 weeks. Assessment of peripheral neuropathy was done at screening, weeks 9 and 21, and for those on BV+ART or PTX+ART, additionally at weeks 3, 6, 15 and 18. KS tumor punch biopsy, serum, plasma and peripheral blood mononuclear cells (PBMCs) were obtained and stored for use in future analyses. Participants also completed ET and ART adherence evaluations and quality of life questionnaires.

Enrollment to ET+ART and initiation of ET+ART in subsequent steps were discontinued in March 2016, based on the recommendation of the Data and Safety Monitoring Board (DSMB) due to ET+ART being less effective than PTX+ART. No safety concerns were identified. ET+ART participants in Step 1 or Step 2, in discussion with the local investigator and in consultation with the protocol CMC, could discontinue ET and enter Step 3. ET+ART participants in Step 3 could discontinue ET and start the remaining chemotherapy regimen in Step 4 in discussion with the local investigator and in consultation with the protocol CMC. Unless otherwise indicated, comparison between ET+ART and PTX+ART was based on the March 2016 data. The study remained open to enrollment and the remaining participants were randomized at Step 1 entry between BV+ART and PTX+ART. The target total sample size was revised to 446.

The DSMB recommended stopping the study in March 2018 due to BV+ART being inferior to PTX+ART. No safety concerns were identified. Study accrual was stopped. Eligible Step 1 PTX+ART participants entered Step 2 to receive PTX+ART; Step 1 and Step 2 BV+ART participants eligible to receive PTX+ART moved to Step 3 to receive PTX+ART. Otherwise, participants permanently transitioned to local care upon arrangement of appropriate oncology and ART, and then went off study. Participants who received ET while on study were followed for 144 weeks after beginning the last cycle of ET.

Comparison between BV+ART and PTX+ART was based on the March 2018 data.

Eligibility criteria: Inclusion Criteria for Step 1:

1. HIV-1 infection
2. Biopsy diagnostic of KS at any time prior to study entry.
3. Current KS stage T1 using ACTG criteria.
4. A minimum of five indicator KS cutaneous marker lesions (or if fewer than five marker lesions are available, the total surface area of the marker lesion(s) must be \>=700 mm\^2) plus an additional two lesions greater or equal to 4x4 mm that are accessible for punch biopsy.
5. CD4+ lymphocyte cell count obtained within 28 days prior to study entry at a DAIDS-approved laboratory.
6. Certain laboratory values, as defined in the protocol, obtained within 14 days prior to study entry.
7. Female study volunteers of reproductive potential must have a negative serum or urine pregnancy test with a sensitivity of 15-25 mIU/mL performed within 48 hours before initiating the protocol-specified medications.
8. All participants must agree not to participate in a conception process (active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization).
9. If participating in sexual activity that could lead to pregnancy, participant must agree that two reliable forms of contraceptives will be used simultaneously while receiving protocol-specified medications, and for 12 weeks after stopping the medications. Study volunteers who are not of reproductive potential (women who have been post-menopausal for at least 24 consecutive months or have undergone hysterectomy and/or bilateral oophorectomy or men who have documented azoospermia) are eligible without requiring the use of contraceptives.
10. Ability to swallow oral medications and adequate venous access.
11. Karnofsky performance status \>= 60 within 28 days prior to entry.
12. Ability and willingness of participant or legal guardian/representative to provide informed consent.

Exclusion Criteria for Step 1:

1. Current chronic, acute, or recurrent serious infections for which the participant has not completed at least 14 days of therapy prior to study entry and/or is not clinically stable.
2. Serious illness requiring systemic treatment and/or hospitalization within 14 days prior to entry.
3. Current or history of known pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), emphysema, bronchiectasis, or diffuse or significant local radiographic interstitial infiltrates on chest x-ray (CXR) or computed axial tomography (CT) scan.
4. Oxygen saturation less than 90% and/or exercise desaturation greater than 4% within 14 days prior to study enrollment.
5. Grade \>=3 peripheral neuropathy (PN) at entry.
6. Breastfeeding.
7. Receipt of ART for more than 42 days immediately prior to entry.
8. Prior or current systemic or locally administered chemotherapy.
9. Prior or current radiation therapy.
10. Prior or current immunotherapy, e.g., interferon alfa.
11. Corticosteroid use at doses above those given as replacement therapy for adrenal insufficiency within the last 30 days prior to study entry.
12. Any immunomodulator, HIV vaccine, live attenuated vaccines, or other investigational therapy or investigational vaccine within 30 days prior to study entry.
13. Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.
14. Active drug or alcohol use or dependence that would interfere with adherence to study requirements.
15. Current or anticipated receipt of any of the prohibited medications listed in section 5.5.2 of the protocol.
16. In the opinion of the investigator, any psychological or social condition, or addictive disorder that would preclude compliance with the protocol.

Inclusion Criteria for Step 2:

1. IERC-confirmed complete response (CR) or partial response (PR) to the chemotherapy regimen used in Step 1.
2. IERC-confirmed KS progression at least 12 weeks after the last dose of Step 1 chemotherapy.
3. Fewer than 72 weeks after Step 1 entry
4. Certain laboratory values, as defined in the protocol, obtained within 14 days prior to Step 2 entry.
5. For females of reproductive potential or females not of reproductive potential who do not have required documentation, negative serum or urine pregnancy test with a sensitivity of 15-25 mIU/mL within 7 days prior to Step 2 entry.
6. Karnofsky performance status \>=50 within 28 days prior to Step 2
7. All participants must agree not to participate in a conception process (active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization).

Exclusion Criteria Step 2:

1. Current chronic, acute, or recurrent infections that are serious, in the opinion of the site investigator, for which the participant has not completed at least 14 days of therapy prior to Step 2 entry and/or is not clinically stable.
2. Severe toxicity to the chemotherapy regimen used in Step 1 requiring discontinuation of study chemotherapy.
3. Serious illness, other than progressive KS, requiring systemic treatment and/or hospitalization within 14 days prior to Step 2 entry.
4. For volunteers who received bleomycin in Step 1

   * Development of of pulmonary fibrosis, COPD, emphysema, bronchiectasis, and diffuse or significant local radiographic interstitial infiltrates on CXR or CT scan that in the opinion of the site investigator would exclude bleomycin use.
   * Oxygen saturation less than 90% or exercise desaturation greater than 4% within the last 30 days prior to Step 2 entry.
5. For volunteers who received Vincristine or Paclitaxel in Step 1, Grade \>=3 PN at Step 2 entry.
6. Breastfeeding.
7. Other concurrent chemotherapy, immunotherapy, or radiotherapy.
8. Systemic corticosteroid use at doses above those given as replacement therapy for adrenal insufficiency within 30 days of Step 2 entry.
9. Receipt of Etoposide (ET) in Step 1.

Inclusion Criteria Step 3:

1. (a) IERC-confirmed KS progression at any time during Step 1 chemotherapy, or (b) IERC-confirmed KS progression fewer than 12 weeks after the last chemotherapy dose in Step 1 in participants who have had an IERC-confirmed CR or PR, or (c) IERC-confirmed KS progression following Step 1 chemotherapy, without any prior response, or (d) IERC-confirmed KS progression in Step 2, or (d) with concurrence of the CMC, there is dose-limiting toxicity after receiving fewer than four cycles of chemotherapy in Step 1 or Step 2, in the absence of a CR or PR, or (e) volunteers otherwise eligible for Step 2 who, in the opinion of the investigator and with concurrence of the CMC, are unlikely to benefit from another course of the same chemotherapy received in Step 1.
2. Fewer than 72 weeks after Step 1 entry.
3. Certain laboratory values, as defined in the protocol, obtained within 14 days prior to Step 3 entry.
4. For females of reproductive potential or females not of reproductive potential who do not have required documentation, negative serum or urine pregnancy test with a sensitivity of 15-25 mIU/mL within 7 days prior to Step 3 entry.
5. Karnofsky performance status \>=50 within 28 days prior to Step 3 entry.
6. All participants must agree not to participate in a conception process (active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization).

Exclusion Criteria Step 3:

1. Current chronic, acute, or recurrent infections that are serious, in the opinion of the site investigator, for which the participant has not completed at least 14 days of therapy prior to Step 3 entry and/or is not clinically stable.
2. Serious illness, other than progressive KS, requiring systemic treatment and/or hospitalization within 14 days prior to Step 3 entry.
3. Eligible for Step 2 entry.
4. For participants who did not receive bleomycin in Step 1 or Step 2:

   * Development of pulmonary fibrosis, COPD, emphysema, bronchiectasis, and diffuse or significant local radiographic interstitial infiltrates on CXR or CT scan that in the opinion of the site investigator would exclude bleomycin use.
   * Oxygen saturation less than 90% or exercise desaturation greater than 4% within the last 30 days prior to Step 3 entry.
5. Grade \>=3 PN at Step 3 entry.
6. Breastfeeding
7. Other concurrent chemotherapy, immunotherapy, or radiotherapy.
8. Systemic corticosteroid use at doses above those given as replacement therapy for adrenal insufficiency within 30 days of Step 3 entry.

Inclusion Criteria Step 4:

1. (a) IERC-confirmed KS progression in Step 3, or (b) With concurrence of the CMC, dose-limiting toxicity after receiving fewer than four cycles of chemotherapy in Step 3, in the absence of a CR or PR, or (c) Current receipt of ET in Step 3.
2. Fewer than 72 weeks after Step 1 entry.
3. Certain laboratory values, as defined in the protocol, obtained within 14 days prior to Step 4 entry.
4. For females of reproductive potential or females not of reproductive potential who do not have required documentation, negative serum or urine pregnancy test with a sensitivity of 15-25 mIU/mL within 7 days prior to Step 4 entry.
5. Karnofsky performance status \>=50 within 28 days prior to Step 4 entry.
6. All participants must agree not to participate in a conception process (active attempt to become pregnant or to impregnate, donate sperm, in vitro fertilization).
7. Receipt of ET in Step 1, Step 2, or Step 3.

Exclusion Criteria Step 4:

1. Current chronic, acute, or recurrent infections that are serious, in the opinion of the site investigator, for which the participant has not completed at least 14 days of therapy prior to Step 4 entry and/or is not clinically stable.
2. Serious illness, other than progressive KS, requiring systemic treatment and/or hospitalization within 14 days prior to Step 4 entry.
3. For participants who did not receive bleomycin in Step 1, Step 2, or Step 3:

   * Development of pulmonary fibrosis, COPD, emphysema, bronchiectasis, and diffuse or significant local radiographic interstitial infiltrates on CXR or CT scan that in the opinion of the site investigator would exclude bleomycin use.
   * Oxygen saturation less than 90% or exercise desaturation greater than 4% within the last 30 days prior to Step 4 entry.
4. Grade \>=3 PN at Step 4 entry.
5. Breastfeeding.
6. Other concurrent chemotherapy, immunotherapy, or radiotherapy.
7. Systemic corticosteroid use at doses above those given as replacement therapy for adrenal insufficiency within 30 days of Step 4 entry.

Primary outcomes:
measure: Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
Secondary outcomes:
measure: Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART
timeFrame: From study entry to week 12
measure: Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART
timeFrame: From study entry to week 12
measure: Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART
timeFrame: From study entry to week 48
measure: Cumulative Rate of Death for ET+ART vs. PTX+ART
timeFrame: From study entry to week 240
measure: Cumulative Rate of Death for BV+ART vs PTX+ART
timeFrame: From study entry to week 240
measure: Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART
timeFrame: From study entry to week 240
measure: Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART
timeFrame: From study entry to week 240
measure: Number of Participants With Objective Response for ET+ART vs. PTX+ART
timeFrame: From study entry up to week 144
measure: Number of Participants With Objective Response for BV+ART vs. PTX+ART
timeFrame: From study entry up to week 144
measure: Duration of Objective Response for ET+ART vs. PTX+ART
timeFrame: From study entry up to week 144
measure: Duration of Objective Response for BV+ART vs. PTX+ART
timeFrame: From study entry up to week 144
measure: Number of Participants With Symptomatic Peripheral Neuropathy (SPN)
timeFrame: Screening, Weeks 3, 6, 9, 12, 15, 18, 21. Assessment of SPN for ET+ART was only done at screening, weeks 9 and 21.
measure: Number of Participants With Peripheral Neuropathy (PN)
timeFrame: Screening, Weeks 3, 6, 9, 12, 15, 18, 21. Assessment of PN for ET+ART was only done at screening, weeks 9 and 21.
measure: Number of Participants With Treatment-related Toxicities and Adverse Events (AEs)
timeFrame: From study entry to week 240
measure: Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART
timeFrame: Baseline, weeks 12, 24, 48
measure: Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART
timeFrame: Baseline, weeks 12, 24, 48
measure: Self-reported Adherence to ART Therapy
timeFrame: At Weeks 6, 12, 18, 30 and 48
measure: Presence of Oral KS
timeFrame: From study entry to week 240
measure: Salivary KSHV
timeFrame: Baseline, weeks 60, 120, 180, 240
measure: Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2
timeFrame: From Step 2 study entry to Step 2 discontinuation, up to 144 weeks
measure: Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3
timeFrame: From Step 3 study entry to Step 3 discontinuation, up to 144 weeks
measure: Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4
timeFrame: From Step 4 study entry to Step 4 discontinuation, up to 96 weeks
Other outcomes:
measure: Quality of Life Measures
timeFrame: Baseline, weeks 60, 120, 180, 240
measure: Immunohistochemical Evaluations of Viral and Cellular Gene Expression
timeFrame: Baseline, 24-48 hours after 2nd chemo-therapy cycle begins
measure: RNA Levels for KSHV Genes
timeFrame: Baseline, weeks 60, 120, 180, 240
measure: Cellular and Humoral Markers of Immune Function and Activation
timeFrame: Baseline, weeks 60, 120, 180, 240
measure: Plasma KS-associated Herpesvirus (KSHV)
timeFrame: Baseline, weeks 60, 120, 180, 240
measure: Peripheral Blood Mononuclear Cell (PBMC) KSHV
timeFrame: Baseline, weeks 60, 120, 180, 240
Locations:
city: Rio de Janeiro
country: Brazil
facility: Instituto de Pesquisa Clinica Evandro Chagas (12101)
city: Eldoret
country: Kenya
facility: Moi University International Clnical Trials Unit
city: Kericho
country: Kenya
facility: KMRI / Walter Reed Project Clinical Research Center
city: Kisumu
country: Kenya
facility: Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460)
city: Blantyre
country: Malawi
facility: Univ. of Malawi, John Hopkins Project
city: Lilongwe
country: Malawi
facility: Malawi CRS (12001)
city: Cape Town
country: South Africa
facility: Family Clinical Research Unit (FAM-CUR) CRS (8950)
state: West Cape
city: Durban
country: South Africa
facility: Durban Adult HIV CRS (11201)
city: Johannesburg
country: South Africa
facility: University of Witwatersrand
city: Kampala
country: Uganda
facility: Uganda Cancer Institute ACTG CRS
city: Harare
country: Zimbabwe
facility: UZ-Parirenyatwa CRS (30313)
Study officials:
affiliation: University of Zimbabwe
name: Margaret Borok-Williams, MD
role: STUDY_CHAIR
affiliation: AIDS Malignancy Consortium
name: Susan E. Krown, MD
role: STUDY_CHAIR
References:
citation: Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989 Sep;7(9):1201-7. doi: 10.1200/JCO.1989.7.9.1201.
citation: Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002 Jan 1;20(1):153-9. doi: 10.1200/JCO.2002.20.1.153.
citation: Krown SE, Moser CB, MacPhail P, Matining RM, Godfrey C, Caruso SR, Hosseinipour MC, Samaneka W, Nyirenda M, Busakhala NW, Okuku FM, Kosgei J, Hoagland B, Mwelase N, Oliver VO, Burger H, Mngqibisa R, Nokta M, Campbell TB, Borok MZ; A5263/AMC066 protocol team. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020 Apr 11;395(10231):1195-1207. doi: 10.1016/S0140-6736(19)33222-2. Epub 2020 Mar 5.